Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367312 · ClinicalTrials.gov registry record · Phase 2
Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI
A Phase 2 study, sponsored by Bastiaan Driehuys.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03367312 is a Phase 2 study that has completed, run by Bastiaan Driehuys. The registered enrollment target is 11 participants.
The verdict
NCT03367312, a Phase 2 study, has completed, sponsored by Bastiaan Driehuys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study seeks to deploy several forms of 129Xe MRI contrast as well as emerging conventional proton MRI techniques for imaging lung structure and perfusion. Specifically, the 129Xe MRI scans will provide 3D images of ventilation and gas exchange, and spectroscopic indices will be evaluated too test gas exchange dynamics with high temporal resolution. The conventional 1H MRi scans will include a free-breathing ultra-short echo time scan that provides images similar to that of a CT scan. This will be done pre, immediately post, and 2-4 hours post inhaled prostacyclin therapy.
Interventions
- DRUG Hyperpolarized 129Xenon gas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03367312
The ClinicalTrials.gov registry entry for NCT03367312 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperpolarized 129Xenon gas is the first listed.
NCT03367312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03367312 about?
NCT03367312 is a clinical study titled "Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI". This study seeks to deploy several forms of 129Xe MRI contrast as well as emerging conventional proton MRI techniques for imaging lung structure and perfusion. Specifically, the 129Xe MRI scans will provide 3D images of ventilation and gas exchange, and spectroscopic indices will be evaluated too te...
What is the current status of trial NCT03367312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-03-29. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT03367312?
The interventions under investigation include: Hyperpolarized 129Xenon gas (DRUG).
Who is sponsoring clinical trial NCT03367312?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.